Regenxbio Total Cash From Financing Activities Over Time
RGNX Stock | USD 9.92 0.09 0.90% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Regenxbio Performance and Regenxbio Correlation. Regenxbio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regenxbio. If investors know Regenxbio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regenxbio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.01) | Revenue Per Share 1.765 | Quarterly Revenue Growth (0.16) | Return On Assets (0.26) | Return On Equity (0.72) |
The market value of Regenxbio is measured differently than its book value, which is the value of Regenxbio that is recorded on the company's balance sheet. Investors also form their own opinion of Regenxbio's value that differs from its market value or its book value, called intrinsic value, which is Regenxbio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regenxbio's market value can be influenced by many factors that don't directly affect Regenxbio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regenxbio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regenxbio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regenxbio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Financing Activities Analysis
Compare Regenxbio and related stocks such as Day One Biopharmaceu, Replimune Group, and Mirum Pharmaceuticals Total Cash From Financing Activities Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DAWN | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 30 M | 297.1 M | 165.9 M | 164 M | 151.3 M |
REPL | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 54.8 M | 101.4 M | 100.2 M | 372.5 M | 6.6 M | 311.3 M | 16.3 M | 15.5 M |
MIRM | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 89.8 M | 127.2 M | 181.3 M | 73.5 M | 109.1 M | 336.6 M | 353.4 M |
RCKT | 2.5 M | 2.5 M | 2.5 M | 17.9 M | 568 K | 125.5 M | 16.0 | 25.4 K | 153.5 M | 177.8 M | 283 M | 37.7 K | 155.3 M | 208.4 M | 218.8 M |
RNA | 594 K | 594 K | 34.3 M | 88 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 89.2 M | 272 M | 176.3 M | 346.2 M | 93.9 M | 135.1 M |
QURE | 140 K | 140 K | 14.9 M | 46.5 M | 84.5 M | 150.4 M | 2.4 M | 90.1 M | 158 M | 248.8 M | 7.4 M | 94.9 M | 1.4 M | 362.7 M | 380.9 M |
PTGX | 9 M | 9 M | 9 M | 9 M | 9 M | 17.4 M | 106.3 M | 65.6 M | 24.1 M | 46 M | 247.6 M | 129.9 M | 18.8 M | 170.5 M | 91.9 M |
PLRX | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 20 M | 87.3 M | 45.5 M | 213.2 M | 2.5 M | 226.9 M | 274.4 M | 288.1 M |
IMCR | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 19.1 M | 101 K | 55.1 M | 115.9 M | 276.3 M | 138.2 M | 34.3 M | 32.6 M |
RVMD | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 22.7 M | 60.8 M | 98.7 M | 422.8 M | 294.2 M | 301.4 M | 1.2 B | 1.3 B |
GLUE | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 15 M | 60.1 M | 377.6 M | 20.5 M | 27.5 M | 26.1 M |
STOK | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 6 M | 115.6 M | 149.8 M | 108.1 M | 1.3 M | 46.4 M | 53 M | 54.9 M |
ANTX | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 3.8 M | 78.5 M | 70.4 M | 85 M | 54.1 M |
PASG | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 46 M | 175.6 M | 228.8 M | 166.7 K | (1.4 K) | 135 K | 128.2 K |
FDMT | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 16 K | 84.6 M | (2.2 M) | 279 M | 118.1 M | 3.1 M | 156.8 M | 100.5 M |
CRNX | (53 K) | (53 K) | (53 K) | (53 K) | (53 K) | (53 K) | (53 K) | 11.8 M | 170.2 M | 67 K | 114.6 M | 252.7 M | 122 M | 388.9 M | 408.4 M |
KZR | 36 K | 36 K | 36 K | 36 K | 36 K | 36 K | 36 K | 49.8 M | 77.9 M | 272 K | 99.6 M | 112.6 M | 127.9 M | 638 K | 606.1 K |
Regenxbio and related stocks such as Day One Biopharmaceu, Replimune Group, and Mirum Pharmaceuticals Total Cash From Financing Activities description
My Equities
My Current Equities and Potential Positions
Regenxbio | RGNX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Location | Maryland; U.S.A |
Exchange | NASDAQ Exchange |
USD 9.92
Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.